Max Flogegård
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Papers in
- Hematology 11
- Multiple Myeloma Research and Treatments 7
- Acute Myeloid Leukemia Research 2
- Chronic Myeloid Leukemia Treatments 2
-
- Lymphoma Diagnosis and Treatment 4
- Co-authors
- Gunilla Enblad (4 shared papers)Gustaf Hedström (2 shared papers)Antonios Valachis (2 shared papers)Hareth Nahi (3 shared papers)Nina Gulbrandsen (1 shared paper)Peter Gimsing (1 shared paper)Erik C. Holmberg (1 shared paper)Øyvind Hjertner (1 shared paper)
- Journals
- British Journal of Haematology (4 papers)Blood (3 papers)Annals of Hematology (1 paper)The Lancet Oncology (1 paper)European Journal Of Haematology (1 paper)
- Partner nations
- SwedenDenmarkUnited States
In The Last Decade
Max Flogegård
17 papers receiving 860 citations
Max Flogegård's Hit Papers
Peers
Comparison fields: 5 of 50
- Hematology 680
- Oncology 55
- Pathology and Forensic Medicine 37
- Emergency Medicine 17
- Immunology 35
Countries citing papers authored by Max Flogegård
This map shows the geographic impact of Max Flogegård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Flogegård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Flogegård more than expected).
Fields of papers citing papers by Max Flogegård
This network shows the impact of papers produced by Max Flogegård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Flogegård. The network helps show where Max Flogegård may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Flogegård, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 319 |
| 2 | 2020 | 203 | |
| 3 | 2011 | 160 | |
| 4 | 2012 | 41 | |
| 5 | 2013 | 41 | |
| 6 | 2022 | 35 | |
| 7 | 2021 | 20 | |
| 8 | 2019 | 15 | |
| 9 | 2018 | 13 | |
| 10 | 2015 | 12 | |
| 11 | 2022 | 12 | |
| 12 | 2009 | 3 | |
| 13 | 2026 | 3 | |
| 14 | 2023 | 2 | |
| 15 | 2012 | 1 | |
| 16 | 2024 | 1 | |
| 17 | 2025 | 1 |
About Max Flogegård
Max Flogegård is a scholar working on Hematology, Pathology and Forensic Medicine, Genetics, Oncology and Public Health, Environmental and Occupational Health, having authored 17 papers that have together received 882 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (7 papers), Lymphoma Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Chronic Lymphocytic Leukemia Research (1 paper), Ethics in Clinical Research (1 paper), Global Cancer Incidence and Screening (1 paper) and Amyloidosis: Diagnosis, Treatment, Outcomes (1 paper). The work is most often cited by research in Hematology (680 citations), Oncology (55 citations), Pathology and Forensic Medicine (37 citations), Emergency Medicine (17 citations) and Immunology (35 citations). Max Flogegård has collaborated with scholars based in Sweden, Denmark and United States. Frequent co-authors include Gunilla Enblad, Gustaf Hedström, Antonios Valachis, Hareth Nahi, Nina Gulbrandsen, Peter Gimsing, Erik C. Holmberg, Øyvind Hjertner, Agneta Swedin and Per Trøllund Pedersen. Their work appears in journals such as British Journal of Haematology, Blood, Annals of Hematology, The Lancet Oncology and European Journal Of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.